MedPath

Fujian Cancer Hospital (Fujian Cancer Institute, Fujian Cancer Prevention and Treatment Center)

🇨🇳China
Ownership
-
Employees
-
Market Cap
-
Website
Clinical Trials
Related News

Apatinib Combined With POF for Second-line Treatment of Gastric Adenocarcinoma

Phase 2
Conditions
Gastric Adenocarcinoma
Interventions
Drug: Apatinib
Drug: POF
First Posted Date
2018-12-27
Last Posted Date
2019-05-10
Lead Sponsor
Fujian Cancer Hospital
Target Recruit Count
26
Registration Number
NCT03788174
Locations
🇨🇳

Rongbo Lin, Fuzhou, China

EGFR-TKIs Combine With Anlotinib as First-line Treatment for Patients With Advanced EGFR Mutation-positive NSCLC

Phase 2
Conditions
EGFR Gene Mutation
Interventions
Drug: erlotinib or gefitinib or icotinib
Drug: Anlotinib
First Posted Date
2018-10-25
Last Posted Date
2018-10-25
Lead Sponsor
Fujian Cancer Hospital
Target Recruit Count
90
Registration Number
NCT03720873
Locations
🇨🇳

Fujian cancer hospital, Fuzhou, Fujian, China

Bevacizumab Plus Capecitabin vs S-1 as Maintenance Treatment Following First-line Chemotherapy in the Patients With Advanced Colorectal Adenocarcinoma

Phase 3
Withdrawn
Conditions
Colorectal Adenocarcinoma
Interventions
Drug: S-1
Drug: Bevacizumab
Drug: Capecitabine
First Posted Date
2018-10-17
Last Posted Date
2021-03-08
Lead Sponsor
Fujian Cancer Hospital
Registration Number
NCT03708536
Locations
🇨🇳

Rongbo Lin, Fuzhou, Fujian, China

Study of the Combination of Apatinib and POF

Phase 2
Conditions
Gastric Adenocarcinoma
Interventions
Drug: Apatinib
Drug: POF
First Posted Date
2018-10-16
Last Posted Date
2018-10-16
Lead Sponsor
Fujian Cancer Hospital
Target Recruit Count
26
Registration Number
NCT03707639
Locations
🇨🇳

Rongbo Lin, Fuzhou, Fujian, China

Nimotuzumab for Recurrent Nasopharyngeal Carcinoma

Phase 2
Conditions
Recurrent Nasopharyngeal Carcinoma
Interventions
Drug: Nimotuzumab
First Posted Date
2018-09-11
Last Posted Date
2018-09-11
Lead Sponsor
Fujian Cancer Hospital
Target Recruit Count
67
Registration Number
NCT03666221
Locations
🇨🇳

Department of radiation oncology, Fujian cancer hospital, Fuzhou, Fujian, China

EBV-TCR-T（YT-E001）for Patients With EBV-positive Recurrent or Metastatic NPC

Phase 2
Conditions
Nasopharyngeal Carcinoma
Interventions
Biological: EBV-TCR-T (YT-E001) cells
First Posted Date
2018-08-27
Last Posted Date
2020-08-11
Lead Sponsor
Fujian Cancer Hospital
Target Recruit Count
20
Registration Number
NCT03648697
Locations
🇨🇳

Fujian Cancer Hospital, Fuzhou, Fujian, China

Cognitive Dysfunction in Patients With Cancer Pain

Conditions
Cognitive Dysfunction
First Posted Date
2018-08-22
Last Posted Date
2018-08-22
Lead Sponsor
Fujian Cancer Hospital
Target Recruit Count
928
Registration Number
NCT03641820
Locations
🇨🇳

Department of Nursing, Fujian Provincial Cancer Hospital, Fuzhou, Fujian, China

Change the Dose Frequency of Controlled-Release Oxycodone to Refractory Pain

Phase 4
Withdrawn
Conditions
Cancer Pains
Interventions
Drug: Increasing the Controlled-Release Oxycodone dose frequency
First Posted Date
2018-08-21
Last Posted Date
2021-03-08
Lead Sponsor
Fujian Cancer Hospital
Registration Number
NCT03639415

Phase I Study of the Combination of Anlotinib With Pemetrexed or Docetaxel

Not Applicable
Conditions
Non-squamous Non-small Cell Lung Cancer
Interventions
Drug: Anlotinib
Drug: Pemetrexed
Drug: Docetaxel
First Posted Date
2018-06-25
Last Posted Date
2018-06-25
Lead Sponsor
Fujian Cancer Hospital
Target Recruit Count
18
Registration Number
NCT03566576

Appaconitine Patch for Oral Mucositis Pain Caused by Chemoradiotherapy in Patients With Nasopharyngeal Cancer

Not Applicable
Conditions
Radiation Induced Oral Mucositis
Interventions
Drug: Lappaconitine Adhesive Patch
Drug: standard care
First Posted Date
2018-05-08
Last Posted Date
2018-05-14
Lead Sponsor
Fujian Cancer Hospital
Target Recruit Count
74
Registration Number
NCT03518489
Locations
🇨🇳

Fujian Cancer Hospital Radiation Oncology Department, Fuzhou, Fujian, China

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy